Background: There are scarce efficacy data on immunotherapy administered to patients with cat or dog allergy.
INTRODUCTION
Data on the efficacy of allergen immunotherapy in patients with cat [1] [2] [3] [4] [5] [6] [7] [8] [9] or dog allergy [3, 5, 10] remain scarce, especially in the case of dog allergy. High dose of standardized extracts have proven effective in treating patients who are allergic to cat. Previous double-blind studies with subcutaneous immunotherapy (SCIT] using standardized catallergen extracts have demonstrated that maintenance doses containing 13.2 µg of Fel d 1 [6] , 13.8 µg Fel d 1 [4] , or 15 µg Fel d 1 [7, 8] reduced symptoms related to cat exposure and brought immunologic changes, [2, 4, 8, [11] [12] [13] . The efficacy of SCIT with standardized dog-allergen extract has shown less efficacy than SCIT with standardized cat-allergen extract [3, 5, 10] , despite showing immunologic changes [12, 14] .
The purpose of the present study was to explore the use of high-dose SCIT in patients with allergic rhinitis and asthma due to cat and dog in real-life clinical practice.
MATERIAL AND METHODS

Patients
We conducted a prospective observational study, selecting consecutive patients with rhinitis and/or asthma due to sensitization to cat or dog and for whom treatment with immunotherapy was indicated [15] . All candidates for inclusion expressed a willingness to initiate SCIT after receiving information on the possible benefits of this therapy approach. For a patient to be included, a strong relation between clinical symptoms and exposure to cat or dog was required, and an additional requisite was positive 
